DV Biomed Current Debt
6539 Stock | TWD 66.90 0.20 0.30% |
DV Biomed holds a debt-to-equity ratio of 0.207. . DV Biomed's financial risk is the risk to DV Biomed stockholders that is caused by an increase in debt.
Given that DV Biomed's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which DV Biomed is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of DV Biomed to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, DV Biomed is said to be less leveraged. If creditors hold a majority of DV Biomed's assets, the Company is said to be highly leveraged.
6539 |
DV Biomed Debt to Cash Allocation
Many companies such as DV Biomed, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
DV Biomed Co has accumulated 249.93 M in total debt with debt to equity ratio (D/E) of 0.21, which may suggest the company is not taking enough advantage from borrowing. DV Biomed has a current ratio of 2.27, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist DV Biomed until it has trouble settling it off, either with new capital or with free cash flow. So, DV Biomed's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like DV Biomed sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for 6539 to invest in growth at high rates of return. When we think about DV Biomed's use of debt, we should always consider it together with cash and equity.DV Biomed Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the DV Biomed's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of DV Biomed, which in turn will lower the firm's financial flexibility.Understaning DV Biomed Use of Financial Leverage
Understanding the structure of DV Biomed's debt obligations provides insight if it is worth investing in it. Financial leverage can amplify the potential profits to DV Biomed's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its cost of debt.
DV Biomed Co., Ltd. manufactures and sells medical-grade skin care products in Taiwan and internationally. The company was founded in 2011 and is based in Taipei, Taiwan. UnicoCell operates under Drug ManufacturersSpecialty Generic classification in Taiwan and is traded on Taiwan OTC Exchange. Please read more on our technical analysis page.
Pair Trading with DV Biomed
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DV Biomed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DV Biomed will appreciate offsetting losses from the drop in the long position's value.Moving together with 6539 Stock
Moving against 6539 Stock
0.63 | 2345 | Accton Technology Corp | PairCorr |
0.53 | 6674 | Compal Broadband Networks | PairCorr |
0.52 | 1591 | Inmax Holding | PairCorr |
0.47 | 1796 | GeneFerm Biotechnology | PairCorr |
0.47 | 3054 | LIWANLI Innovation | PairCorr |
The ability to find closely correlated positions to DV Biomed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DV Biomed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DV Biomed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DV Biomed Co to buy it.
The correlation of DV Biomed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DV Biomed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DV Biomed moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DV Biomed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for 6539 Stock Analysis
When running DV Biomed's price analysis, check to measure DV Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DV Biomed is operating at the current time. Most of DV Biomed's value examination focuses on studying past and present price action to predict the probability of DV Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DV Biomed's price. Additionally, you may evaluate how the addition of DV Biomed to your portfolios can decrease your overall portfolio volatility.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.